16 active not recruiting, 9 terminated, 8 recruiting, 5 completed. 20 Phase 2, 18 Phase 1, 2 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Clinical Stage III Cutaneous Melanoma AJCC v8: new trials by email Literature Review of Clinical Stage III Cutaneous Melanoma AJCC v8 trials Research Report on Clinical Stage III Cutaneous Melanoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy Biospecimen Collection, Internet-Based Intervention, Medical Device Usage and Evaluation - Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Not yet recruiting | City of Hope Medical Center | 8 | 2026-12-23 | 2026-06-05 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma Biopsy Procedure, Biospecimen Collection, Placebo Administration - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | ECOG-ACRIN Cancer Research Group | 120 | 2026-02-20 | 2026-09-15 |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Home Health Encounter, Nivolumab, Patient Monitoring - Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 50 | 2024-04-30 | 2026-10-02 |
| The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors Fermented Wheat Germ Extract - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Suspended | University of California, Davis | 100 | 2023-06-02 | 2026-07-01 |
| Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors Rigosertib, Pembrolizumab, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 7 | 2023-05-09 | 2026-09-16 |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 150 | 2022-12-06 | 2026-10-20 |
| Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study Internet Mobile Technology, Internet-Based Intervention, Questionnaire Administration - Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8 | Not applicable | Completed | Fred Hutchinson Cancer Center | 549 | 2022-10-23 | 2026-01-23 |
| Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study Anti-PD-L1 Monoclonal Antibody IMC-001, Punch Biopsy - Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma | Phase 1 | Terminated | Mayo Clinic | 3 | 2022-10-17 | 2025-12-03 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Active not recruiting | University of Southern California | 173 | 2021-11-24 | 2026-10-05 | |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 60 | 2021-10-15 | 2026-09-29 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel - Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2021-09-30 | 2026-10-06 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma Ipilimumab, Nivolumab, Lymph Node Assessment - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Terminated | Mayo Clinic | 6 | 2021-09-16 | 2024-12-10 |
| Bone Loss in Melanoma Survivors Receiving Immunotherapy Biospecimen Collection, Dual X-ray Absorptiometry - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Terminated | M.D. Anderson Cancer Center | 12 | 2021-05-10 | 2025-08-17 | |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Atezolizumab, Avelumab, Durvalumab - Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-14 | 2026-04-30 |
| Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer Best Practice, Biospecimen Collection, Endoscopic Procedure - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 800 | 2021-02-21 | 2026-07-15 |
Showing 20 of 42. Sign in to see all of them.
Melanoma (28) · Lung Neoplasms (11) · Carcinoma, Non-Small-Cell Lung (9) · Carcinoma, Renal Cell (7) · Neoplasm Metastasis (7) · Colorectal Neoplasms (6) · Ovarian Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (6) · Carcinoma, Transitional Cell (5) · Carcinoma, Hepatocellular (4) · Carcinoma, Merkel Cell (4) · Carcinoma, Basal Cell (3) · Sarcoma, Kaposi (3) · Triple Negative Breast Neoplasms (3) · Uterine Cervical Neoplasms (3)
Neoplasms by Site (34) · Neoplasms (33) · Neoplasms by Histologic Type (32) · Neoplasms, Germ Cell and Embryonal (29) · Neoplasms, Nerve Tissue (29) · Neuroectodermal Tumors (29) · Neuroendocrine Tumors (29) · Nevi and Melanomas (28) · Skin Diseases (28) · Skin Neoplasms (28) · Skin and Connective Tissue Diseases (28) · Neoplasms, Glandular and Epithelial (14) · Urogenital Diseases (14) · Carcinoma (13) · Female Urogenital Diseases (13)
Specimen Handling (16) · Nivolumab (14) · Magnetic Resonance Spectroscopy (11) · pembrolizumab (10) · Biopsy (9) · CTLA-4 Antigen (9) · Ipilimumab (9) · Immunoglobulin G (5) · Disulfides (4) · Cyclophosphamide (3) · Prednisone (3) · atezolizumab (3) · deltacortene (3) · prednylidene (3) · Bevacizumab (2)
National Cancer Institute (NCI) (11) · Mayo Clinic (9) · M.D. Anderson Cancer Center (8) · ECOG-ACRIN Cancer Research Group (2) · Fred Hutchinson Cancer Center (2) · Roswell Park Cancer Institute (2) · City of Hope Medical Center (1) · F. Stephen Hodi, MD (1) · Fudan University (1) · Jonsson Comprehensive Cancer Center (1) · Rutgers, The State University of New Jersey (1) · University of California, Davis (1) · University of Southern California (1) · Vanderbilt-Ingram Cancer Center (1)
United States (40) · Canada (1) · China (1) · Ireland (1) · Uganda (1)
Evan J Lipson (2) · Roxana S. Dronca, M.D. (2) · Ahmad Tarhini (1) · Anastasios Dimou, M.D. (1) · Anastasios Dimou, MD (1) · Ari M Vanderwalde (1) · Aung Naing, MD (1) · Douglas Johnson, MD (1) · Erez Baruch, MD,PHD (1) · F. Stephen Hodi, MD (1) · Geoffrey T Gibney (1) · Haiying Cheng (1) · Jewel Samadder, M.D. (1) · John M Kirkwood (1) · Joseph M Tuscano, MD (1)
PMID 29784747, PMID 31154457, PMID 32503950, PMID 33909232, PMID 34562230, PMID 34825282, PMID 34965890, PMID 35080914, PMID 35537412, PMID 36166727, PMID 36416836, PMID 36648215, PMID 36692933, PMID 36821617, PMID 36856617, PMID 37104746, PMID 37129197, PMID 37328287, PMID 37592104, PMID 38252910, PMID 38365756, PMID 39356983, PMID 39633321, PMID 39816915, PMID 39945382, PMID 40234093, PMID 40580957, PMID 40721981, PMID 40811146, PMID 41680482, PMID 42847673
U10CA180888 (4), U10CA180820 (3), UM1CA186691 (2), F30CA250326 (1), P30CA014089 (1), P30CA015704 (1), P30CA016056 (1), P30CA033572 (1), P30CA093373 (1), R01CA164333 (1), R01CA221854 (1), R21CA197878 (1), R37CA256867 (1), U01CA062490 (1), U01CA132194 (1)